



Company Contact - Jim Dorsey  
**BioClinica, Inc.**  
267-757-3040

Trade Media – Rachel Summers  
**Diccicco Battista Communications**  
484-342-3600 ext. 244  
[rsummers@dbcworks.com](mailto:rsummers@dbcworks.com)

Investor Contact - Michael Porter  
Financial Media - Bill Gordon  
**Porter, LeVay & Rose, Inc.**  
212-564-4700

---

**FOR IMMEDIATE RELEASE**

**BIOCLINICA, INC. TO SPONSOR AND LEAD DISCUSSION AT KEY CLINICAL TRIAL INDUSTRY EVENTS**

- Experts Will Present Perspectives on Regulatory Guidances and Driving Clinical Trial Efficiency -

**NEWTOWN, PA, January 10, 2012** – BioClinica<sup>®</sup>, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at upcoming industry conferences during the first quarter of 2012. BioClinica experts will discuss industry trends and also demonstrate its advanced suite of clinical trial technologies and service solutions.

The events include:

**Imaging in Clinical Trials – An Overview of the New FDA Guidance and Its Impact**

**January 12, 2012 11:00 a.m. (EST)**

**\*WEBINAR\***

The FDA has recently issued a draft Guidance for Industry on Standards for Clinical Trial Imaging Endpoints. This guidance describes procedures recommended for interpreting and collecting medical images in clinical trials. This webinar will provide a brief historical perspective of the regulatory view of medical imaging in clinical trials that led to this guidance followed by a comprehensive overview of the document as it currently stands. The potential impact of this guidance to sponsors, sites and core labs will be discussed.

To register please visit: <http://www.bioclinica.com/webinar-imaging-in-clinical-trials-new-fda-guidance/>

**The New FDA Draft Guidance – What It Means to Me as a Site, a CRA and a Data Manager**

**Part 1: January 19, 2012 11:00 a.m. (EST)**

**Part 2: January 26, 2012 11:00 a.m. (EST)**

**\*WEBINAR\***

The FDA has recently issued draft guidances for Industry on Standard for Clinical eSource and Risk-Based Approaches to monitoring which have a broad impact on almost all facets of the clinical trial management. This webinar series will discuss the impact of recent FDA guidances on industry and approaches to prepare to implement new strategies.

To register please visit: <http://www.bioclinica.com/webinar-the-new-fda-draft-guidances-what-it-means-to-me/>

-more-

**Life Sciences Innovation Forum**  
**January 26 – 27, 2012**  
**Marriott Forrestal Village Conference Center**  
**Princeton, NJ**

BioClinica will lead a panel discussion “Implementing a New Approach to Clinical Trial Management, the Clinical Trials Framework.” Topics will include:

- How traditional systems have failed to meet their promise
- Driving new efficiencies and processes to improve drug development throughout the clinical phase
- Enhanced collaboration – approaches to access, share and analyze clinical data more efficiently

Panel members:

- Dan Delaney, Clinical Project Manager, CR BARD
- Robert Leonard, Chief Information Officer, Harvard Clinical Research Institute
- Brandon Cheal, Commodity Manager, R&D, Johnson & Johnson
- Peter Benton, President, eClinical Solutions, BioClinica, Inc.
- Miguel Amador, Clinical Project Manager, Johnson & Johnson Vision Care, Inc.

**Outsourcing in Clinical Trials West Coast**  
**February 15 - 16, 2012**  
**San Francisco Airport Marriott Waterfront**  
**San Francisco, CA**

Outsourcing in Clinical Trials joins major pharma and biotech manufacturers to debate potential solutions to complex challenges. Due to a difficult economic environment, it is important to make the best use of all available resources. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.

**Partnerships in Clinical Trials 2012**  
**March 5 - 7, 2012**  
**The Marriot World Center**  
**Orlando, FL**  
**Booth # 215**

BioClinica will demonstrate its expanded suite of integrated clinical trial services that maximize efficiency and manageability of the clinical trial process at this clinical operations and outsourcing event. This event attracts nearly 2,000 of the world's most strategic clinical trial executives to one location.

**24<sup>th</sup> Annual Euro DIA Meeting**  
**March 26 –28, 2012**  
**Bella Center**  
**Copenhagen, Denmark**  
**Booth # 138**

This conference hosts more than 3,000 professionals from over 50 countries, including professionals from the biopharmaceutical industry, contract service organizations, academic research centers, regulatory agencies and health ministries, including representatives from the EMEA, FDA and regulatory agencies throughout Europe will be in attendance. As BioClinica's global delivery spans 15,000 sites in 88 countries, this conference will showcase its integrated suite of clinical trial services to influential members of the global biopharmaceutical industry.

**CBI's 5<sup>th</sup> Annual Forum on Clinical Trials Management Systems (CTMS)**

**March 22 - 23, 2012**

**Doubletree Hotel Philadelphia Center City**

**Philadelphia, PA**

CBI's 5<sup>th</sup> Annual Forum on Clinical Trial Management Systems is an event for clinical business and IT professionals to learn from the challenges and successes of their industry counterparts. This meeting addresses the adoption and integration of CTMS systems across the organization as well as working with drug development partners. BioClinica's Jeremiah Rehm, eClinical Solutions Specialist, will co-present Workshop B on March 22<sup>nd</sup> from 7:30 a.m. -12:15 p.m. on "Building the Pathways Between Sponsors, CROs and Site to Share CTMS Data." During this workshop attendees will learn the best practices in developing pathways between sponsors and CROs, what common pitfalls to avoid and lastly, how to determine what information should be shared.

**About BioClinica, Inc.**

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit [www.bioclinica.com](http://www.bioclinica.com)

*Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.*

#####